Jonathan Zaroff, MD
Cardiovascular Disease · San Francisco, CANPI 1902857279
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,635 of the $1,797 with a category attached, or 91.0%. Abbott accounts for 73.2% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2024 at $1,105 and has fallen 81.1% since, to $209 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in CA, where the typical reported total is $2,142.
Across 18 payments — averaging $99.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Edwards Lifesciences$482
Across 2 payments — averaging $394,575 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$789K
What the payments were for
- Travel & lodging$1,63591%
- Food & beverage$1629%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 11 | $1,314 |
| Edwards Lifesciences | 7 | $482 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRICLIP$200
How this compares
$1,797 in reported general payments places this provider in the 45th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 21 | $508,358 |
| EntrestoSacubitril/Valsartan | 19 | $25,150 |
| EliquisApixaban | 12 | $23,238 |
| Repatha SureclickEvolocumab | 22 | $21,394 |
| PradaxaDabigatran Etexilate Mesylate | 41 | $12,231 |
| JardianceEmpagliflozin | 16 | $8,157 |
| Metoprolol Succinate | 159 | $2,207 |
| Atorvastatin Calcium | 155 | $1,939 |
| Furosemide | 75 | $1,280 |
| Amlodipine Besylate | 80 | $994 |
| Flecainide Acetate | 22 | $877 |
| Bumetanide | 20 | $865 |
| Amiodarone Hcl | 25 | $769 |
| Torsemide | 41 | $752 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 48 | $743 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in San Francisco
- Philip SagerSan Francisco$675K
- Javid MoslehiSan Francisco$307K
- Tony ChouSan Francisco$301K
- Lloyd KleinSan Francisco$149K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.